| Characteristics | Severe/critical patients (n = 35) | Severe patients who died (n = 19) |
| Antibiotic therapy: -Ceftriaxone -Cefotaxime -Azitromicin -Clavamox -Amikacin -Metronidazol |
34 (97.1%) 3 (8.6%) 20 (57.1%) 6 (17.1%) 2 (5.7%) 2 (5.7%) |
19 (100%) 1 (5.3%) 11 (57.9%) 2 (10.5%) 2 (10.5%) 1 (5.3%) |
| Dexametasone | 25 (71.4%) | 9 (47.4%) |
| Sem dexametasona | 10 (28.6%) | 10 (52.6%) |
| Mean time between hospitalization and start of dexamethasone (days) | 1.2 (0 - 8) | 1.1 (0 - 3) |
| Enoxaparin | 17 (48.6%) | 7 (36.8%) |
| No enoxaparin | 18 (51.4% | 12 (63.2%) |
| Mean time between hospitalization and initiation of enoxaparin (days) | 1.6 (0 - 8) | 2.4 (0 - 8) |
| Mean time between disease onset and severity | 4. 2 (1 - 9) dias | 4 (1 - 9) dias |
| Onset of disease and severity <24 h 48 - 72 h 4 - 7 days 8 - 14 days Over 14 days |
3 (8.6%) 11 (31.4%) 19 (54.3%) 2 (5.7%) 0 |
2 (10.5%) 8 (42.1%) 7 (36.8%) 2 (10.5%) 0 |
| Mean time between hospitalization and severity (days) | 1 (0 - 6) | 1.4 (0 - 6) |
| Hospitalization and severity (n) <24 h 48 - 72 h 4 - 7days 8 - 14 days Over 14 days |
26 (74.3%) 7 (20%) 2 (5.7%) 0 0 |
12 (63.2%) 5 (26.3%) 2 (10.5%) 0 0 |
| Complications: Respiratory failure Shock Neurological picture/convulsion Embolism |
21 (60%) 3 (8.6%) 5 (14.3%) 1 (2.9%) |
19 (100%) 2 (10.5%) 4 (21.1%) 1 (5.3%) |